Search
This study demonstrates how clonal hematopoiesis (CH)–derived mutations could lead to erroneous reporting and treatment recommendations when tumor-only sequencing is employed. If data about the blood are not part of test results, mutations present in the blood may be misread as mutations in the tumor, which can potentially affect the therapies patients receive. Data presented at the annual meeting of the American Society of Clinical Oncology by Ahmet Zehir, PhD, Director of Clinical Bioinformatics at Memorial Sloan Kettering Cancer Center (MSK) was simultaneously published in JAMA Oncology on June 5.
Learn the difference between CT Scan and MRI and how doctors use these imaging techniques to diagnose and stage cancer.
As part of Memorial Sloan Kettering’s 33rd annual academic convocation on May 11, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences awarded PhDs to four graduates.
In honor of his extraordinary contributions to improving the diagnosis and treatment of childhood cancer, Richard O’Reilly, Chairman of the Department of Pediatrics and Director of the Bone Marrow Transplantation Program at MSK, will receive the first Society of Memorial Sloan Kettering Prize.
MSK researchers shared their latest research developments at the 2021 meeting of the American Association for Cancer Research.
The Prospective Registry Of Multi-Plex Testing (PROMPT) - a new online, volunteer registry for individuals who have been tested for inherited mutations in cancer-causing genes - will provide data vital to improving our understanding of newly discovered, cancer-associated genes and allow current and future generations to better interpret and benefit from knowledge of their genomes.
Learn how MSK is joining forces with the City of New York to expand access to the COVID-19 vaccine.
Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical genomic sequencing by MSK-IMPACT™, a powerful diagnostic test developed at MSK to provide detailed genetic information about a patient’s cancer.
Chemotherapy after immune checkpoint inhibitors (ICIs) may improve survival rates in patients with heavily pretreated, recurrent ovarian cancer.
Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.